key: cord-0956612-xsws7dlq
authors: Pasha, Terouz; Zatorska, Anna; Sharipov, Daulet; Rogelj, Boris; Hortobágyi, Tibor; Hirth, Frank
title: Karyopherin abnormalities in neurodegenerative proteinopathies
date: 2021-05-21
journal: Brain
DOI: 10.1093/brain/awab201
sha: d0d64d8c5e313e226544a2e383b3cac8f5e97fa6
doc_id: 956612
cord_uid: xsws7dlq

Neurodegenerative proteinopathies are characterised by progressive cell loss that is preceded by the mislocalisation and aberrant accumulation of proteins prone to aggregation. Despite their different physiological functions, disease-related proteins like tau, alpha-synuclein, Tar DNA binding protein-43, Fused in sarcoma and mutant Huntingtin, all share low complexity regions that can mediate their liquid-liquid phase transitions. The proteins’ phase transitions can range from native monomers to soluble oligomers, liquid droplets and further to irreversible, often-mislocalised aggregates that characterise the stages and severity of neurodegenerative diseases. Recent advances into the underlying pathogenic mechanisms have associated mislocalisation and aberrant accumulation of disease-related proteins with defective nucleocytoplasmic transport and its mediators called karyopherins. These studies identify karyopherin abnormalities in amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer’s disease, and synucleinopathies including Parkinson’s disease and dementia with Lewy bodies, that range from altered expression levels to the subcellular mislocalisation and aggregation of karyopherin alpha and beta proteins. The reported findings reveal that in addition to their classical function in nuclear import and export, karyopherins can also act as chaperones by shielding aggregation-prone proteins against misfolding, accumulation and irreversible phase-transition into insoluble aggregates. Karyopherin abnormalities can, therefore, be both the cause and consequence of protein mislocalisation and aggregate formation in degenerative proteinopathies. The resulting vicious feedback cycle of karyopherin pathology and proteinopathy identifies karyopherin abnormalities as a common denominator of onset and progression of neurodegenerative disease. Pharmacological targeting of karyopherins, already in clinical trials as therapeutic intervention targeting cancers such as glioblastoma and viral infections like COVID-19, may therefore represent a promising new avenue for disease-modifying treatments in neurodegenerative proteinopathies.

Neurodegeneration is the selective and progressive loss of neurons, eventually leading to cognitive and behavioural deficits for which currently no cure or effective treatments are available. 1 can be divided into three groups based on their major role in nucleocytoplasmic transport as either exportins, importins or for bidirectional transport. For example, KPNBs such as exportin 4 (XPO4) or exportin 5 (XPO5) mediate nuclear export of cargos, 37-41 whereas KPNB1 or TNPO1 and TNPO2 (also called KPNB2 and KPNB2B, respectively) mediate nuclear import (see Table 2 , also for synonyms and cargos). Despite significant differences in protein structure, localisation and function of the majority of disease-associated proteins, their nucleocytoplasmic shuttling is mediated by karyopherins.

The nucleus of cells provides a protective environment through tightly regulated protein import and export. 42 While smaller proteins as well as ions, salts and nucleotides can enter the nucleus via passive diffusion, 34 proteins larger than 40-65kDa require binding to nuclear transport receptors to traverse the nuclear pore complex (NPC) . 26 This process (Figure 2 ) is regulated by three key elements: the nuclear pore complex, nuclear transport factors of the karyopherin families and a Ras-related nuclear (RAN) protein gradient. 43 The nuclear pore complex consists of three rings: the nucleoplasmic ring, the middle inner ring and the cytoplasmic ring that form an aqueous channel spanning the nuclear envelope. 44 At the molecular level, it consists of an assembly of approximately 30 nucleoporins (NUPs) classified into six groups based on their localisation. 45 The nucleoporins are also grouped by their molecular function into those that form the NPC scaffold, the trans-membrane nucleoporins and the phenylalanine and glycine (FG) containing nucleoporins -where phase separation occurs. In the absence of stable nucleoporin complexes, the nucleus would be pore-free with a continuous nuclear envelope. 43 Ran, a small GTPase protein, drives the direction of cargo transport, depending on its bound nucleotide state. The nuclear regulator RCC1 functions as a guanine nucleotide exchange factor and maintains RanGTP levels by facilitating GDP-GTP exchange. In the cytoplasm, Ran GTPase activating protein (Ran-GAP) and Ran binding protein 1 (RanBP1) catalyse the hydrolysis of GTP to GDP. Cooperation of these two systems forms a Ran gradient, which guides directionality of nucleopcytoplasmic transport (Figure 2 ) and facilitates the rapid and selective cargo transport into and out of the nucleus. 26 Karyopherins are central to nucleocytoplasmic trafficking as they recognise the nuclear localisation signal or nuclear export signal (NES) of cargo proteins. 31 In the 'classical' nuclear import pathway, 46 cargo proteins such as TDP-43 contain a 'classical' NLS (cNLS), which KPNAs bind to mediate nuclear import. cNLSs are either monopartite or bipartite sequences.

Whilst monopartite sequences contain a single cluster of basic amino acids (Lys/Arg) as exemplified by the SV40 large T antigen NLS 126-PKKKRRV-132, 47 bipartite sequences are made up of two clusters of basic residues separated by an unconserved linker region (e. g.

nucleoplasmin . 48 During classical nuclear import (Figure 2) , the cargo-KPNA bipartite complex binds to KPNB1 creating a trimeric complex (cargo-KPNA-KPNB1) that interacts with the FG motifs of the nucleoporins in the central channel, and subsequently, driven by the RanGTP/GDP gradient, this complex translocates to the nucleus. 42, 49 In the nucleus the trimeric complex starts to dissociate once RanGTP binds to KPNB1, with the physical separation of KPNB1 and KPNA. Subsequent dissociation of the KPNA-cargo complex is slow and can be catalysed by CSE1L/CAS that also mediates export of KPNA. The KPNA, RanGTP and CSE1L/CAS proteins are then recycled back to the cytoplasm (Figure 2 ). In addition to the cNLS-dependent pathway, other import pathways involve non-classical NLSs, which unlike cNLSs bind directly to KPNBs without the need for interaction with KPNA. 34 One such example is the Proline-Tyrosine NLS (PY-NLS) motif of FUS, which is directly imported via TNPO1 and 2 (KPNB2 and KPNB2B). 7,50,51 Although FUS and TDP-43 have putative nuclear export signal sequences, it should be noted that TDP-43 and FUS could also be exported through the nucleus via passive diffusion. 52,53 Bioinformatics analysis indicates that the nuclear export signals in TDP-43 and FUS are non-functional and both proteins can be exported independent of the export receptors XPO1 and XPO5. 52

Karyopherin abnormalities have been implicated in ALS and FTD with TDP pathology; [15] [16] [17] [18] [19] [20] 54 in Alzheimer's disease and FTD with Tau pathology; 55-60 in synucleinopathies; [61] [62] [63] [64] [65] [66] and in cell and animal models of Huntington's disease [67] [68] [69] [70] , suggesting karyopherin-associated pathology as a common denominator in the aetiology of neurodegenerative proteinopathies. In the following sections we review how karyopherin abnormalities manifest in these neurodegenerative diseases which is summarised in Table 3 .

Frontotemporal Dementia with TDP pathology ALS and FTD are part of a common disease spectrum with overlapping clinical, pathological and genetic features. 71, 72 ALS is a debilitating and ultimately fatal disease, characterised by the progressive loss of upper and lower motor neurons which inevitably leads to degeneration of corticospinal tracts and muscle wasting. 73, 74 In contrast, FTD is characterised by progressive neuronal atrophy which occurs in the frontal and temporal lobes with the resulting loss of cortical tissue leading to personality and behavioural changes, and/or a gradual impairment of language skills. 72,75 A common pathological feature found in both diseases are abnormally aggregated cytoplasmic inclusions of TDP-43 76,77 that characterise 97% of ALS cases and approximately 45% of patients with FTD 71 which are therefore termed FTD-TDP in contrast to FTD cases with tau pathology termed FTD-Tau.

Reduced protein levels of KPNA2 and CAS are observed in FTD-TDP frontal cortex 54 and reduced KPNB1 levels are found in the spinal cord of patients with ALS. 78 Immunohistochemical analysis of nucleoporins in ALS revealed an irregular, fractured nuclear pore complex, 79 possibly preventing the nuclear import of TDP-43. In addition, irregular, disrupted nuclear staining for NUP62 or KPNB1 has been reported in sporadic ALS with TDP-43 mislocalisation providing further evidence for disruption of the nuclear pore complex in TDP-43 pathologies. 80 Moreover, cell culture experiments revealed that KPNB1 and CAS knockdown dysregulates the classical nuclear import of TDP-43, leading to its cytoplasmic accumulation comparable to disease pathology. 54 Corresponding phenotypes were also observed in the most common genetic form of ALS and FTD caused by an intronic hexanucleotide repeat expansion (GGGGCC) in the C9ORF72 gene, termed C9ALS/FTD. 21,22,81-84 Several pathogenic mechanisms have been related to the C9ORF72 mutation, including haploinsufficiency 85, 86 and homozygous loss of C9ORF72 function, 87 as well as toxic gain of function of the repeat RNA, 83, [88] [89] [90] and the accumulation of dipeptide repeat proteins (DPRs) that are translated from G4C2 mRNA templates through repeat-associated non-ATG translation (RAN translation). 89, 91 However, the exact contribution of each of these mechanisms to onset and progression of disease in C9ALS/FTD is still inconclusive. 92 Functional studies in C9ALS/FTD cell and animal models identified defective nucleocytoplasmic transport and nuclear pore complex deficits as potential pathogenic mechanisms underlying neurodegeneration. [21] [22] [23] [24] 93, 94 These findings are supported by rescue experiments in yeast and Drosophila models of C9ALS/FTD, which identified importins, exportins, Ran-GTP cycle regulators and nuclear pore components as modifiers of G4C2 RNA and DPR-mediated neurodegeneration. 21,23,24 Moreover, a recent study, using a permeabilised cell assay, showed that arginine-rich DPRs bind KPNB1, ultimately leading to dose-and length-dependent disruption of nuclear import. 95 Of note, this study also revealed that transport disruption was neither due to sequestration of NCT components, nor to blockade of the FG nucleoporin-mediated permeability barrier, but rather due to perturbed KPNB-related cargobinding. 95 Comparable nucleocytoplasmic transport and nuclear pore complex deficits were also reported in models of TDP-43 proteinopathy. 15, 16 These studies provide experimental evidence that accumulating cytosolic TDP-43 causes cytoplasmic mislocalization of KPNAs in Drosophila models of C9ALS/FTD, a phenotype that is also observed in post-mortem frontal cortex tissue of C9FTD patients and sporadic cases of FTD-TDP. 15, 16 Cytosolic TDP-43 functions in the stabilisation, translation and transport of mRNA. 96 However, imbalanced cytoplasmic accumulation of TDP-43 can induce its nuclear depletion and aggregate formation, 97 cellular phenotypes that are both related to onset and progression of disease. 98 Nuclear depletion of TDP-43, through decreased expression or aggregate formation, has also been shown to lead to reduced levels of RanBP1, suggesting that TDP-43 mislocalisation may be both cause and consequence of errors in nucleocytoplasmic transport. 98 However, the initiating causes leading to cytoplasmic accumulation of TDP-43 remain elusive.

Interaction studies have identified direct protein-protein interactions between TDP-43 and KPNA2 54 and KPNA4 15 , in addition to TDP-43 targeting the pre-mRNA of KPNA4 and to a lesser extent that of KPNA2. 99 Furthermore, cytoplasmic TDP-43 droplets that are not associated with stress granules have been shown to sequester KPNA4 and NUP62 and induce mislocalization of RanGap1, Ran, and NUP107. 20 These findings support the feedback loop model proposed by Solomon et al. 16 , whereby cytoplasmic, non-aggregated droplets of TDP-43 recruit karyopherins which in turn causes nucleocytoplasmic transport deficits. Of note, KPNAs also bind arginine-rich DPRs, 93 the most toxic DPR species observed in models of C9ALS/FTD, 100,101 which in turn impairs KPNA/KPNB mediated nuclear import, including cargo transport of TDP-43. 102 Moreover, cell culture studies revealed that DPRs can be sequestered into cytoplasmic inclusions by β-sheet protein aggregates, including fragments of TDP-43. 70 Furthermore, experiments in cell culture 54 and in Drosophila 103 revealed the depletion of KPNB1 and KPNAs directly contributes to impaired nuclear import and cytoplasmic accumulation of TDP-43. These data suggest a vicious cycle of TDP-43 and karyopherin abnormalities 16 and in turn impaired nucleocytoplasmic transport and a defective nuclear pore complex, that trigger onset and progression of disease in ALS and FTD-TDP.

Alzheimer's disease is the most common cause of dementia, accounting for up to 75% of all dementia cases. 104 Patients suffer from insidiously progressive disturbances in memory and other cognitive capabilities such as dysfunction in language, visuospatial deficits and impaired executive function. 105 AD-related proteinopathy is characterized by neurofibrillary tangles enriched in hyperphosphorylated tau, and amyloid plaques comprising Aβ fragments of aberrantly cleaved Amyloid precursor protein. 4, 106 Karyopherin abnormalities in Alzheimer's disease have been repeatedly reported, yet how they contribute to disease formation and/or progression is only starting to emerge.

Accumulated and aggregated KPNA2/Importin-1 has been identified in neurofibrillary tangles 57 and in Hirano bodies in hippocampal CA1 neurons of AD patient cases. 56 cDNA microarray studies using AD patient brain samples identified abnormally upregulated levels of KPNA3, 55 while KPNA6 upregulation was identified in association with small non-coding RNAs in AD-affected brain. 58 In addition to KPNA abnormalities, several members of the KPNB family have been found to be mis-localised, accumulated or aggregated in Alzheimer's disease patient brain. KPNB1 and KPNB2 were found in cytoplasmic granules in hippocampal neurons, while KPNB2 accumulation was also detected in tangle-bearing cells of Alzheimer's disease cases. 107 Expression of KPNB1 and XPO5/exportin-5 were both found to be upregulated in AD cases and both proteins co-localized with hyperphosphorylated tau. 59 These data suggest that karyopherin abnormalities may play a direct role in tau pathology related to Alzheimer's disease and possibly also FTD-Tau.

In support of this hypothesis, experiments using a Drosophila model of tauopathy revealed that tau-induced nuclear envelope invaginations sequestered the karyopherin beta family member XPO1/exportin-1. 108 Another study using AD patient brain material together with transgenic mouse models of FTD-Tau identified a direct link between tau pathology and nucleocytoplasmic transport deficits. 60 Using co-immunoprecipitation from human AD brain tissue, these studies demonstrated direct binding between tau and Nup98 and that tau interacts with nuclear pore proteins enriched in phenylalanine-glycine (FG) repeat domains. In addition, these FG-motif nucleoporins were shown to mis-localize from and in turn disrupt the nuclear membrane in primary cortical neurons derived from transgenic mouse models of FTD-Tau. 60

As a likely consequence of these NPC deficits, alterations in active protein import and export were observed including decreased expression of Ran required for energy-dependent nucleocytoplasmic shuttling. 60 This reduction in Ran expression and reduced nucleocytoplasmic transport has also been observed in an earlier study using Alzheimer's disease brain samples and neuroblastoma cells, 109 suggesting that nucleocytoplasmic transport deficits may directly contribute to tau pathology and disease progression. This is further supported by in vitro experiments which showed that Nup98 triggers tau aggregation and accelerates tau fibrilization seen in Alzheimer's disease and tauopathy brains. 60

Despite these functional insights into tau phenotypes and nucleocytoplasmic transport deficits, it remains to be established whether the karyopherin abnormalities observed in Alzheimer's disease patient brain 55-59,107 are a cause or a consequence of tau pathology. A possible pathogenic mechanism might be related to the functional link between nuclear pore proteins enriched in FG-motifs like Nup98 and karyopherins of the beta family. These FG-motif Nups and KPNBs are known to interact with each other at the nuclear membrane 110, 111 and their functional interactions are essential to allow repeated Ran-dependent cycles of nucleocytoplasmic shuttling. 112 These data suggest that alterations in levels or localisation of FG-Nups, Ran and/or KPNBs could trigger tau pathology -and vice versa -and lead to the cellular and molecular phenotypes already observed in transgenic mouse models of FTD-Tau. 60

Synucleinopathies are a group of neurodegenerative disorders that include Parkinson's disease (PD), Parkinson's disease with dementia (PDD), dementia with Lewy bodies (DLB) and

multiple system atrophy (MSA). 113, 114 Their common pathological feature is the accumulation and aggregation of α-synuclein (α-syn) in Lewy bodies (LB) found in neurons and glial cells, and in Lewy neurites (LN) within neuronal processes. 66, [115] [116] [117] Native α-syn is found in presynaptic terminals of neurons where it acts as a chaperone for neurotransmitter release. 118 Its initial discovery in Torpedo identified α-syn not only in synaptic terminals but also in neuronal nuclei, 119 suggesting a physiological function in both synapse and the nucleus. Indeed, recent experiments using transgenic mice and human cell culture revealed translocation of αsyn to the nucleus where it modulates DNA repair, 120 raising the question how α-syn can shuttle into the nucleus.

α-syn does not possess a nuclear localisation signal and due to its small size of 14kDa 121 may enter the nucleus via passive diffusion. Recent findings however, identified three intermediates that interact with α-syn and together translocate into the nucleus: by direct binding of α-syn to the retinoic acid receptor and its calcium-dependent nuclear import; 122 by sumoylation of αsyn and its subsequent binding to KPNA6 which mediates transport into the nucleus; 123 by interaction with TRIM28 124 and its karyopherin-alpha mediated nuclear import. 125 Dysfunction of either pathway has been directly implicated in α-syn pathology in transgenic mice and in cell culture experiments expressing human mutant forms of α-syn, as well as in post-mortem brain tissue of DLB cases. 120, 122, 126 These findings could explain the pathological phenotypes observed in synucleinopathies in which α-syn has been detected in aberrant forms in the nucleus 120, 127, 128 and in presynaptic terminals [129] [130] [131] [132] where it can spread across synaptically connected brain regions. 133, 134 Consistent with these findings, karyopherin abnormalities have been associated with synucleinopathies. Alterations in KPNB1 expression were identified using microarray analysis of tissue material derived from PD patients with a triplication in the α-syn encoding SNCA gene. 65, 135 Lewy body formation triggered by prefibrillary α-syn was found to alter the expression levels of KPNA7 and XPO1/exportin-1. 66 The PD-related α-syn mutation G51D was shown to cause nuclear aggregation, 136 while nuclear aggregation of α-syn was shown to be mitigated by targeted knockdown of KPNA2. 62 Cell culture studies revealed that α-syn mediated cytotoxicity caused upregulation of KPNB3 61 and involved interaction with KPNA3. 137 In addition to these phenotypes directly related to α-syn accumulation, several other studies reported karyopherin abnormalities in cell and animal models of familial forms of PD that are characterised by α-syn pathology. KPNA2 and KPNA6 have been identified as substrates of LRRK2/PARK8 64 whose mutations cause one of the most common forms of PD. 138, 139 Mutant DJ-1/PARK7 140 was shown to interact with KPNB2 in an oxidative stressdependent manner leading to its mislocalisation. 63 FBXO7/PARK15 which requires XPO1 for its normal localisation 141 was found mislocalised together with α-syn in Lewy bodies, Lewy neurites and cytoplasmic inclusions in glial cells in both PD and MSA cases. 142 Despite this multitude of phenotypes, it should be noted that unlike in ALS, FTD and AD cases, conspicuous karyopherin pathology has not been reported in any of the synucleinopathies to date. It therefore seems likely that the detected phenotypes described above are a consequence rather than a cause contributing to the cellular and molecular mechanisms underlying synucleinopathies. However, this situation may change with future work specifically focusing on karyopherin abnormalities and their potential role in the onset and progression of α-syn pathology.

Huntington's disease is an autosomal dominant disorder characterised by neurodegeneration and gliosis in the striatum and cortex, 143 leading to progressive loss of motor function, psychiatric symptoms, and cognitive impairment. 144 HD is caused by a CAG triplet repeat expansion encoding for a polyglutamine (poly-Q) tract in the N-terminus of Huntingtin (HTT). 145 Expansions of >36-39 Glutamine residues trigger disease, and longer poly-Q stretches above this threshold cause early onset Huntington's disease. 146, 147 Huntingtin is a large (∼350 kDa) protein that shuttles between the cytoplasm and nucleus; 148 it contains a XPO1/CRM1-dependent nuclear export signal at its carboxyl-terminus 149,150 and its nuclear import occurs via its PY-NLS by the TNPO/KPNB2 pathway. 68, 151 In mutant Huntingtin, the poly-Q domain is flanked by the first 17 amino acids at the N-terminus (Nt17) and by a poly-Proline stretch at its C-terminus. Mutant Huntingtin is more prone to proteolysis, resulting in smaller fragments of the N-terminus containing the poly-Q expansion of exon 1. 152 Nt17 plays an important role in Huntingtin aggregation and toxicity, in addition to acting as another nuclear export signal via interactions with XPO1/CRM1 in an α-helical and RanGTPdependent manner. 149 The subcellular localisation and actual function of wildtype Huntingtin is still debated, 153, 154 however there is consensus that poly-Q expanded mutant Huntingtin causes gain of function proteinopathy in both the nucleus and the cytoplasm. 144 Consistent with this hypothesis, both intranuclear and cytoplasmic aggregates have been observed in HD patient brains 155, 156 while cell culture experiments using human embryonic kidney 293T cells, neuroblastoma cells and mouse primary neurons transfected with fragments of mutant Huntingtin revealed its nuclear and cytoplasmic aggregation. 70 Moreover, in the striatum and cortex of HD mouse models, mutant Huntingtin formed both nuclear and cytoplasmic aggregates, which resulted in the accumulation of mRNA in the nucleus and an overall reduction in mRNA levels. 70 159 Despite these experimental evidences in cell and animal models of Huntington's disease, conspicuous karyopherin pathology has not been reported so far in brain of patient cases.

Interestingly, however, it has been shown that HD-related CAG repeat expansion RNAs can also function as a template for repeat-associated non-AT (RAN) translation. The resulting homo-polymeric RAN translation products include poly-Ala, poly-Ser, poly-Leu, and poly-Cys peptides that have been detected in brains of Huntington's disease patients, especially in regions of microglial activation and degenerative apoptotic cell loss, as well as throughout the degenerating cerebellar layers of juvenile-onset Huntington's disease cases. 162 These data indicate that the aetiology of Huntington's disease may share similarities with C9ALS/FTD, both in its RAN translation-derived peptide accumulation 161, 163 and in nuclear transport deficits. 70, 161 However, further work is required to establish whether karyopherin pathology characterises patient brain cases and whether these phenotypes are mere consequences of, or directly contribute to mutant Huntingtin, poly-Q and RAN-derived peptide pathology that have been detected in cell and animal models of Huntington's disease. proteins with low complexity regions into droplets and hydrogels, tend to accumulate in membrane-less compartments such as P granules, paraspeckles, nucleoli and stress granules and are very sensitive to changes in temperature, salt, pH or molecular concentration. 169, 170 These environmental alterations characterize protein accumulation and cellular stress observed in neurodegenerative diseases. [12] [13] [14] Recent studies showed that tau, 166 

Previously known for their role in nucleocytoplasmic transport, karyopherins are now also recognised for their important functions as chaperones and molecular switches in the pathogenesis of neurodegenerative proteinopathies (Figure 3) . 13, 14, 183 In is associated with a vicious cycle of KPNA dysfunction that is accompanied by depletion of KPNB1 and a dysfunctional nuclear pore complex. 15 Arginine residues appear to be critical to aberrant phase separation and karyopherin-mediated chaperoning as overexpression of arginine-containing DPRs derived from RAN translated, C9ALS/FTD related G4C2 repeat RNA, can induce the assembly of stress granules, triggering the co-localisation of Ran and karyopherins into these membraneless organelles. 187 The resulting decrease in karyopherin availability impairs karyopherin-mediated cargo transport and chaperone function, thereby increasing cytoplasmic accumulation and phase transitions, which ultimately leads to disease-related fibrillization and aggregate formation.

Corresponding molecular and cellular phenotypes have been observed in AD, FTD-Tau and synucleinopathies. Liquid-liquid phase separation of tau protein was shown to initiate tau aggregation 166, 174, 188, 189 that was significantly enhanced by FTD-tau associated mutations including P301L-tau linked to inherited tauopathy. 173 Tau positive neurofibrillary tangles and Hirano bodies were found enriched in KPNA2/Importin-1 aggregates, 56,57 while KPNB1 and XPO5 were found co-localised with hyperphosphorylated tau in affected neurons. 59 α-syn has been shown to undergo spontaneous liquid-liquid phase separation which was accelerated by disease-related mutations A53T, E46K and S129E and formation of fibrils 167 that could mature into Lewy body-like assemblies. 181 Of note, Lewy body formation related to synucleinopathies has been associated with altered KPNA7 and XPO1/exportin-1 expression, 66 while inhibition of KPNA2 impaired the pathological accumulation of α-syn in the nucleus. 62 Similarly, triggered by its disease-related poly-Q tracts, mutant huntingtin exon1 was shown to form liquid-like assemblies that could convert to solid fibrillar structures. 165 These findings suggest that karyopherin abnormalities are interlinked with alterations of aggregation-prone proteins that can phase separate into disease-related intracellular inclusions and aggregates. In line with these observations, work on nucleocytoplasmic transport receptors,

including KPNB3, showed that karyopherins can act as molecular chaperones, shielding basic domains of positively charged proteins and preventing their aggregation. 102, 187 Together, these data indicate that both karyopherin abnormalities and affected karyopherin-cargo binding promote phase transition which accelerates protein mislocalisation and aggregate formation characteristic of neurodegenerative proteinopathies. As a result of these new findings, it is becoming increasingly evident that karyopherins can act as chaperones comparable to molecular disaggregases 14, 190, 191 that protect aggregation-prone proteins against misfolding, accumulation and irreversible phase-transition into insoluble aggregates. It is therefore reasonable to consider karyopherins as therapeutic targets for the treatment of neurodegenerative diseases for which currently no cure or effective treatments are available.

Current treatments like Riluzole for ALS 192 they are usually upregulated. [194] [195] [196] As a result, several compounds have been developed to target nuclear import and export receptors 197 In neurodegenerative diseases, karyopherins are generally downregulated and mislocalized, which together with impaired nucleocytoplasmic transport and defective chaperone function leads to aberrant phase transition and the subsequent accumulation and aggregation of affected proteins. 14, 191 Recent studies demonstrate that targeting karyopherins can reverse aberrant phase transition and extract aggregated proteins from stress granules. 17-20, 102 Thus, targeting karyopherins, especially their chaperone function, provides a potential novel therapeutic avenue to shield and maintain vulnerable proteins in their native and soluble state, thereby protecting them against phase transition, mislocalisation and aberrant aggregate formation, ultimately protecting affected neurons against cytotoxicity and degenerative loss.

The role of compounds inhibiting nuclear transport of specific cargo substrates has been reported for their use as anti-cancer and anti-viral agents, with more than 20 nuclear transport inhibitors being identified, [196] [197] [198] including Mifepristone, Ivermectin and Verdinexor. [199] [200] [201] [202] Inhibitors of XPO1/CRM1 like Verdinexor, commonly also known as selective inhibitors of nuclear export (SINE) compounds, have been developed via structure-based drug design. 198 Previous studies investigating SINE compounds focused on their use as anti-cancer and antiviral agents, 197 however they are also candidates for the development of therapeutic strategies to target neurodegeneration. 203 For example, XPO1 inhibition in preclinical models of inflammatory demyelination and axonal damage resulted in attenuation of disease progression. 203 These findings suggest that pharmacological targeting of karyopherin function might represent a new strategy for disease-modifying treatments of neurodegenerative proteinopathies.

However, given the different topology of disease-related protein accumulation -nuclear and/or cytoplasmic -a more balanced application will be required that considers not only nuclear transport inhibitors but also their targeted gain of function which will require careful assessment and calibration. Karyopherins modulate an essential cellular process, energydependent nucleocytoplasmic transport of cargo proteins required for cellular homeostasis.

Any interference or manipulation of this process may therefore cause unwanted side effects affecting the localisation and function of cargo proteins essential for neuronal and glial function. It will be of great interest to await and analyse the outcome of currently ongoing clinical trials targeting the KPNA/KPNB1 interface as a strategy to combat several types of cancer such as leukemia and glioblastoma, as well as viral infections including Dengue fever and COVID-19. 196, 197, 206 If proven to be clinically safe, some of these compounds might be suitable for repurposing as a novel therapeutic strategy for the targeted treatment of neurodegenerative proteinopathies.

Nucleocytoplasmic transport is a fundamental process that moves macromolecules across the nuclear membrane, thereby allocating proteins to their principal destination of activity, which is an essential requirement for proper cell function and viability. Key players in this process are karyopherins that mediate the transport of cargo proteins in and out of the nucleus. The mislocalisation of proteins and their subsequent accumulation in the nucleus or cytoplasm are characteristic features, and likely the direct cause, of several neurodegenerative proteinopathies. Why these proteins mislocalise and accumulate in the first place, has remained elusive and the lack of insights into the underlying pathogenic mechanisms constitutes a major obstacle for the development of efficient therapeutic strategies to go beyond current symptomatic treatments.

Despite their differences in function, ranging from nucleic acid processing by TDP-43, to taumediated microtubule stabilisation and chaperone activity of alpha-synuclein in synaptic terminals, all these proteins harbour low complexity regions that make them intrinsically vulnerable to phase transitions of their aggregation state. Phase transitions can be initiated by changes in cellular acidity, temperature and alterations in pH or salt but also by protein mutations, all of which have been associated with neurodegeneration. However, in vivo determination of these pathomechanisms, their detection in patient tissue and a direct role in disease formation and/or progression remain to be shown, and although first generation preclinical biomarkers of liquid-liquid phase separation are becoming available, their use and efficiency remains to be established. 207 Nucleocytoplasmic transport deficits and in particular karyopherin abnormalities are now recognised as a major player, and possibly a trigger, in mediating the mislocalisation and accumulation of disease-related proteins in degenerative proteinopathies, especially in ALS and FTD. Furthermore, karyopherins can also act as chaperones by shielding proteins from irreversible phase transitions, thereby retaining their targets in a soluble form and thus devoid of disease-related aggregation comparable to disaggregase activity. It is currently unclear and remains to be elucidated, how these chaperone functions are exerted, whether they include specific amino acids/protein interaction domains and how these interactions are accomplished.

Thus, an exciting area of future research will be to determine how karyopherins exert their chaperone and disaggregase activity. Work in this area will lead to both a better understanding of how neurodegenerative diseases develop and may uncover novel treatment opportunities.

Pharmacological targeting of karyopherins represents a promising new strategy for therapeutic intervention in neurodegenerative diseases. It remains a major task for an ever-growing elderly population to identify therapies that can stop or at least ameliorate degenerative cell loss. Even Table 2 for details on all KPNB family members. Protein sequences were obtained from UniProt (see Table 1 and Table 2 for ID numbers); Clustal

Omega was used for sequence alignment. Abbreviations: KPNA, karyopherin alpha; KPNB, karyopherin beta/; cNLS, canonical nuclear localisation signal; NES, nuclear export signal;

CAS, cellular apoptosis susceptibility protein. Right, schematic diagram of the classical nuclear import and export pathway. During nuclear import, KPNB1 binds to KPNA, which itself is bound to the classical nuclear localisation signal (cNLS) of cargo, forming a trimeric complex. KPNA also exerts chaperone function to cargo-cNLS by shielding basic residues from hydrophobic/ionic interactions, which maintains a cargo protein in its native soluble state. KPNB1 

World Health Organization. Global action plan on the public health response to dementia 2017-2025. Geneva: World Health Organization

Misfolded protein aggregates: mechanisms, structures and potential for disease transmission

Staging of brain pathology related to sporadic Parkinson's disease

Self-propagation of pathogenic protein aggregates in neurodegenerative diseases

A systematic survey identifies prions and illuminates sequence features of prionogenic proteins

Cell-free formation of RNA granules: Bound RNAs identify features and components of cellular assemblies

Phosphorylation of the FUS low-complexity domain disrupts phase separation, aggregation, and toxicity

Structure of FUS protein fibrils and its relevance to self-assembly and phase separation of low-complexity domains

Phase Separation: Linking Cellular Compartmentalization to Disease

Protein phase separation: A new phase in cell biology

Therapeutic dissolution of aberrant phases by nuclearimport receptors

TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD

A feedback loop between dipeptide-repeat protein, TDP-43 and karyopherin-a mediates C9orf72-related neurodegeneration

Alzheimer's Disease

Analysis of alpha-synuclein-associated proteins by quantitative proteomics

The nuclear accumulation of alpha-synuclein is mediated by importin alpha and promotes neurotoxicity by accelerating the cell cycle

Reactive oxygen species-mediated DJ-1 monomerization modulates intracellular trafficking involving karyopherin β2

Leucine-rich repeat kinase 2 exacerbates neuronal cytotoxicity through phosphorylation of histone deacetylase 3 and histone deacetylation

Gene co-expression network analysis for identifying genetic markers in Parkinson's disease -a three-way comparative approach

The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration

Expanded polyglutamine domain possesses nuclear export activity which modulates subcellular localization and toxicity of polyQ disease protein via exportin-1

Identification of a karyopherin β1/β2 prolinetyrosine nuclear localization signal in huntingtin protein

Brain region-and age-dependent dysregulation of p62 and NBR1 in a mouse model of Huntington's disease

Cytoplasmic protein aggregates interfere with nucleocytoplasmic transport of protein and RNA

Converging mechanisms in ALS and FTD: Disrupted RNA and protein homeostasis

Amyotrophic lateral sclerosis and non-tau frontotemporal lobar degeneration

Amyotrophic lateral sclerosis, Primary lateral sclerosis and Spinal muscular atrophy

Decoding ALS: from genes to mechanism

Frontotemporal dementia

TDP-43 is a component of ubiquitinpositive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis

Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis

Calpain-dependent disruption of nucleo-cytoplasmic transport in ALS motor neurons

Nuclear Contour Irregularity and Abnormal Transporter Protein Distribution in Anterior Horn Cells in Amyotrophic Lateral Sclerosis

Impaired nucleoporins are present in sporadic Amyotrophic Lateral Sclerosis motor neurons that exhibit mislocalization of the 43-kDa TAR DNA-Binding Protein

TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS

Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72

Rademakers, R. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS

Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion

C9ORF72 ALS/FTD human induced motor neurons

Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic

RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia

Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions

The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS

Van Den Bosch, L. C9orf72 loss-of-function: a trivial, standalone or additive mechanism in C9 ALS/FTD?

C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles

Phase separation of C9orf72 dipeptide repeats perturbs stress granule dynamics

C9orf72 arginine-rich dipeptide repeat proteins disrupt karyopherin-mediated nuclear import

TDP-43 and FUS en route from the nucleus to the cytoplasm

Disturbance of Nuclear and Cytoplasmic TAR DNA-binding Protein (TDP-43) Induces Disease-like Redistribution, Sequestration, and Aggregate Formation

Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation

Characterizing the RNA targets and position-dependent splicing regulation by TDP-43

C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins

Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death

Nuclear Import Receptors Directly Bind to Arginine-Rich Dipeptide Repeat Proteins and Suppress Their Pathological Interactions

Cytosolic calcium regulates cytoplasmic accumulation of TDP-43 through Calpain-A and Importin alpha3

Epidemiology of Alzheimer's disease: occurrence, determinants, and strategiestoward intervention

A systemic view of Alzheimer diseaseinsights from amyloid-β metabolism beyond the brain

National Insitute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer's Dement

The distribution of karyopherin beta proteins in Alzheimer's disease

Tau-induced nuclear envelope invagination causes a toxic accumulation of mRNA in Drosophila

Reduced RAN expression and disrupted transport between cytoplasm and nucleus

Alzheimer's disease pathophysiology

Structural basis for the interaction between FxFG nucleoporin repeats and importin-beta in nuclear trafficking

The nucleoporin Nup98 is a site for GDP/GTP exchange on ran and termination of karyopherin beta 2-mediated nuclear import

Promiscuous binding of Karyopherinβ1 modulates FG nucleoporin barrier function and expedites NTF2 transport kinetics

100 years of Lewy pathology

The Synucleinopathies: Twenty Years On

Goedert, M. α-Synuclein in Lewy bodies

Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies

Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders

Mechanisms of a-synuclein induced synaptopathy in Parkinson's disease

Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal

Alpha-synuclein is a DNA binding protein that modulates DNA repair with implications for Lewy body disorders

Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease

Sharon, R. α-Synuclein Translocates to the Nucleus to Activate Retinoic-Acid-Dependent Gene Transcription

Sumoylated -synuclein translocates into the nucleus by karyopherin 6

TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau

Identification and characterization of a nuclear localization signal of TRIM28 that overlaps with the HP1 box

Depleting Trim28 in adult mice is well tolerated and reduces levels of α-synuclein and tau

A quantitative investigation of neuronal cytoplasmic and intranuclear inclusions in the pontine and inferior olivary nuclei in multiple system atrophy

Nuclear localization and phosphorylation modulate pathological effects of alpha-synuclein

Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies

Synaptic phosphorylated α-synuclein in dementia with Lewy bodies

Synaptic proteins predict cognitive decline in Alzheimer`s disease and Lewy body dementia

Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach

Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen

Goedert, M. alpha-Synuclein filaments from transgenic mouse and human synucleinopathy-containing brains are major seed-competent species

Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus

The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells

Endonuclease G mediates α-synuclein cytotoxicity during Parkinson's disease

Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease

Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology

Heutink, P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism

A Competitive binding mechanism between Skp1 and exportin 1 (CRM1) controls the localization of a subset of F-box proteins

FBXO7 immunoreactivity in α-synucleincontaining inclusions in Parkinson disease and multiple system atrophy

Huntington's disease: a clinical review

CAG repeat size and clinical presentation in Huntington's disease

Trinucleotide repeat length and progression of illness in Huntington's disease

Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease

The huntingtin N17 domain is a multifunctional CRM1 and ran-dependent nuclear and cilial export signal

An N-terminal nuclear export signal regulates trafficking and aggregation of huntingtin (Htt) protein exon 1

Transportin-1 and Transportin-2: protein nuclear import and beyond

Huntingtin is degraded to small fragments by calpain after ischemic injury

Huntingtin localisation studies -a technical review

The Biology of Huntingtin

Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain

Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

Network organization of the huntingtin proteomic interactome in mammalian brain

Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice

Polyglutamine-Expanded Huntingtin Exacerbates Age-Related Disruption of Nuclear Integrity and Nucleocytoplasmic Transport

RAN translation in Huntington Disease

RPS25 is required for efficient RAN translation of C9orf72 and other neurodegenerative diseaseassociated nucleotide repeats

Van Den Bosch, L. Molecular dissection of FUS points at synergistic effect of low-complexity domains in toxicity

A liquid to solid phase transition underlying pathological Huntingtin exon1 aggregation

Tau protein liquid-liquid phase separation can initiate tau aggregation

Atypical structural tendencies among low-complexity domains in the Protein Data Bank proteome

Are aberrant phase transitions a driver of cellular aging?

Liquid phase condensation in cell physiology and disease

Liquid-liquid phase separation of the microtubule-binding repeats of the Alzheimer-related protein Tau

Regulatory mechanisms of tau protein fibrillation under the conditions of liquid-liquid phase separation

Liquid-liquid phase separation induces pathogenic tau conformations in vitro

Wolozin, B. TIA1 potentiates tau phase separation and promotes generation of toxic oligomeric tau

The role of liquid-liquid phase separation in aggregation of the TDP-43 low-complexity domain

Detection of TAR DNA-binding protein 43 (TDP-43) oligomers as initial intermediate species during aggregate formation

Aggresome formation and liquid-liquid phase separation independently induce cytoplasmic aggregation of TAR DNA-binding protein 43

TDP-43 α-helical structure tunes liquidliquid phase separation and function

Molecular interactions underlying liquid-liquid phase separation of the FUS lowcomplexity domain

Natural Selection on the Phase-Separation Properties of FUS during 160 My of Mammalian Evolution

Observation of an α-synuclein liquid droplet state and its maturation into Lewy body-like assemblies

Contrasting pathology of the stress granule proteins TIA-1 and G3BP in tauopathies

Phase separation-deficient TDP43 remains functional in splicing

DNA-binding protein 43 (TDP-43) liquid-liquid phase separation is mediated by just a few aromatic residues

Formation and maturation of phaseseparated liquid droplets by RNA-binding proteins

Stress granule assembly disrupts nucleocytoplasmic transport

The proline-rich domain promotes Tau liquid-liquid phase separation in cells

Liquid-Liquid Phase Separation of Tau Driven by Hydrophobic Interaction Facilitates Fibrillization of Tau

Designer protein disaggregases to counter neurodegenerative disease

Combating deleterious phase transitions in neurodegenerative disease

Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis. Ther

Alzheimer Disease: An update on pathobiology and treatment strategies

Critical Review Targeting Nuclear Transporters in Cancer: Diagnostic, Prognostic and Therapeutic Potential

Karyopherins in cancer

Antivirals that target the host IMPα/β1-virus interface

Inhibitors of nuclear transport

Controlling the gatekeeper: Therapeutic targeting of nuclear transport

Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus

Nuclear localization of dengue virus (DENV) 1-4 nonstructural protein 5

Plasmodium falciparum signal recognition particle components and anti-parasitic effect of ivermectin in blocking nucleocytoplasmic shuttling of SRP

In vitro toxicity and efficacy of verdinexor, an exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individuals

Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination

Loss of dynamic RNA interaction and aberrant phase separation induced by two distinct types of ALS/FTD-linked FUS mutations

TDP43 nuclear export and neurodegeneration in models of amyotrophic lateral sclerosis and frontotemporal dementia

The past, present, and future of CRM1/XPO1 inhibitors

Liquid-liquid phase separation drives skin barrier formation

Cytoplasmic poly-GA aggregates impair nuclear import of TDP-43 in C9orf72 ALS/FTLD

Karyopherin α-3 is a key protein in the pathogenesis of spinocerebellar ataxia type 3 controlling the nuclear localization of ataxin-3

The deubiquitinase ataxin-3 requires Rad23 and DnaJ-1 for its neuroprotective role in Drosophila melanogaster

NF-κB Is Transported into the Nucleus by Importin α3 and Importin α4

Nuclear export as a novel therapeutic target: The CRM1 connection

Scyl1 facilitates nuclear tRNA export in mammalian cells by acting ath nuclear pore complex

XPO5 promotes primary miRNA processing independently of RanGTP

Exportin 6: a novel nuclear export receptor that is specific for profilin.actin complexes

Exportin 7 defines a novel general nuclear export pathway

Xpo7 is a broad-spectrum exportin and a nuclear import receptor

Importin beta, transportin, RanBP5 and RanBP7 mediate nuclear import of ribosomal proteins in mammalian cells

FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations

A bimodular nuclear localization signal assembled via an extended double-stranded RNA-binding domain acts as an RNA-sensing signal for transportin 1

Transportin2 functions as importin and mediates nuclear import of HuR. Proc. Natl

Transportin-SR, a nuclear import receptor for SR proteins

Importins fulfil a dual function as nuclear import receptors and cytoplasmic chaperones for exposed basic domains

Signal recognition particle protein 19 is imported into the nucleus by importin 8 (RanBP8) and transportin

Importin-11, a nuclear import receptor for the ubiquitinconjugating enzyme, UbcM2

Importin 13: a novel mediator of nuclear import and export

MSA, multiple system atrophy

We thank D. Solomon, R.B. Parsons and M. Atwal for comments on the manuscript. 

The authors declare no competing interests. Pumroy et al., 27 Nishimura et al., 54 Khsoravi et al., 208 Sowa et al., 209 Tsou et al., 210 IPOA-8 n/a n/a n/a n/a n/a Desmond et al., 68 Jaekel and Görlich, 218 Neumann et al., 219 Barraud 15 Solomon et al., 16 Nishimura et al. 54

Accumulating TDP-43 causes cytoplasmic mislocalization in Drosophila model of C9ALS/FTD;Depletion of KPNA directly contributes to impaired nuclear import and cytoplasmic accumulation of TDP-43.Chou et al., 15 Solomon et al., 16 Park et al. 103 

In ALS models, XPO1 inhibition showed neuroprotective effects against c9orf72 related disease. Zhang et al. 21 CAS Reduced levels in FTD-TDP frontal cortex; Knockdown of CAS dysregulates the import of TDP-43.Nishimura et al. 54

Reduced levels in spinal cords of patients with ALS; Irregular and disrupted nuclear staining in sporadic ALS with TDP-43; Depletion of KPNB1 directly contributes to impaired nuclear import and cytoplasmic accumulation of TDP-43; ALS related mutations in FUS reduce its sensitivity to the chaperone activity of KPNB1, ultimately leading to increased phase separation.Solomon et al., 16 Hofweber et al., 17 Yamashita et al., 78 Aizawa et al., 80 Park et al. 103 TNPO 1 ALS related mutations in FUS reduce its sensitivity to the chaperone activity of TNPO1, ultimately leading to increased phase separation.Hofweber et al. 17

Accumulation and aggregation of KPNA2 is found in neurofibrillary tangles and Hirano bodies of hippocampal CA1 neurons of AD patients. Found in cytoplasmic granules in hippocampal neurons and in tangle-bearing cells of AD cases.

Tau-induced nuclear envelope invaginations sequester XPO1 in a Drosophila model of tauopathy.Cornelison et al. 108

Targeted knockdown linked to nuclear aggregation of -syn; Substrate of LRRK2/PARK8.Ma et al., 62 Han Ma et al., 62 Zhao et al. 142 

Alterations in the expression level of PD patients with a triplication in the SNCA locus encoding -syn.George et al., 65 Devine et al. 135

Mutant DJ-1/PARK7 was shown to interact with KPNB2 in an oxidative stress-dependent manner leading to its mislocalisation. Woerner et al., 70 Langfelder et al. 159 

Binding partner of mHtt in mouse brain expressing mHtt expanded with 97 poly-Q; Target of mHtt in genomics and proteomics study of transgenic mice expressing mHtt.Shirasaki et al., 158 Langfelder et al. 159 

Binding partner of mHtt in mouse brain expressing mHtt expanded with 97 poly-Q; Target of mHtt in genomics and proteomics study of transgenic mice expressing mHtt.Shirasaki et al., 158 Langfelder et al. 159 

Target of mHtt in genomics and proteomics study of transgenic mice expressing mHtt.Langfelder et al. 159 

Binding partner of mHtt in mouse brain expressing mHtt expanded with 97 poly-Q.Shirasaki et al. 158 CAS Binding partner of mHtt in mouse brain expressing mHtt expanded with 97 poly-Q.Shirasaki et al. 158 Abbreviations: -syn, alpha-synuclein; AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; FTD-TDP, frontotemporal